ABUS
Arbutus Biopharma Corporation
Price Chart
Latest Quote
$4.25
-0.10 (-2.30%)
Current Price
| Previous Close | $4.35 |
| Open | $4.34 |
| Day High | $4.36 |
| Day Low | $4.21 |
| Volume | 1,124,752 |
Stock Information
| Shares Outstanding | 197.54M |
| Total Debt | $3.91M |
| Cash Equivalents | $95.23M |
| Revenue | $191.44M |
| Net Income | $160.72M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $839.54M |
| P/E Ratio | 5.12 |
| EPS (TTM) | $0.83 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $748.22M |
| Sales | $191.44M |
| Income | $160.72M |
| Book/sh | $1.32 |
| Cash/sh | $0.48 |
| Employees | 19 |
Financial Ratios
| Quick Ratio | 54.00 |
| Current Ratio | 54.26 |
| Debt/Eq | 1.50 |
Returns & Margins
| ROA | 49.18% |
| ROE | 94.73% |
| Gross Margin | 89.34% |
| Operating Margin | 94.41% |
| Profit Margin | 83.95% |
Ownership
| Insider Ownership | 20.46% |
| Institutional Ownership | 71.90% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -25.71 |
| P/S | 4.39 |
| P/B | 3.22 |
Analyst Data
| Recommendation | none |
| Target Price | $5.10 |
Technical Indicators
| SMA20 | $4.38 |
| SMA50 | $4.38 |
| SMA200 | $4.38 |
| RSI | 50.39 |
| ATR | 0.1943 |
| Shares Float | 121.37M |
| Short Float | 12.38% |
| Short Ratio | 9.14 |
| Volatility | 0.63 |
| Rel Volume | 0.76 |
Performance History
| Week | -6.80% |
| Month | -3.85% |
| Quarter | -6.18% |
| 6 Months | -4.06% |
| YTD | -10.90% |
| Year | +24.63% |
| 3 Years | +70.68% |
| 5 Years | +50.18% |
| 10 Years | +2.66% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $4.25 | 1,124,752 |
| 2026-06-04 | $4.35 | 732,100 |
| 2026-06-03 | $4.35 | 1,730,000 |
| 2026-06-02 | $4.26 | 1,750,100 |
| 2026-06-01 | $4.48 | 841,400 |
| 2026-05-29 | $4.56 | 2,383,700 |
| 2026-05-28 | $4.60 | 1,029,300 |
| 2026-05-27 | $4.64 | 3,672,900 |
| 2026-05-26 | $4.64 | 2,326,800 |
| 2026-05-22 | $4.35 | 847,300 |
| 2026-05-21 | $4.44 | 2,357,600 |
| 2026-05-20 | $4.37 | 2,400,600 |
| 2026-05-19 | $4.20 | 869,000 |
| 2026-05-18 | $4.17 | 911,400 |
| 2026-05-15 | $4.24 | 1,410,800 |
| 2026-05-14 | $4.35 | 926,200 |
| 2026-05-13 | $4.31 | 1,575,700 |
| 2026-05-12 | $4.31 | 1,025,900 |
| 2026-05-11 | $4.39 | 767,300 |
| 2026-05-08 | $4.34 | 752,800 |
| 2026-05-07 | $4.35 | 923,900 |
| 2026-05-06 | $4.42 | 1,008,500 |
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
đ° Latest News
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals
Zacks âĸ 2026-05-04T06:49:00Z
Modernaâs Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway.
Barrons.com âĸ 2026-05-01T18:35:00Z
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
Zacks âĸ 2026-05-01T15:32:00Z
Moderna Q1 2026 earnings beat on international COVID vaccine sales
Quartz âĸ 2026-05-01T13:05:58Z
Moderna sees revenue bump from international COVID vaccine sales
BioPharma Dive âĸ 2026-05-01T12:27:28Z
Moderna Reports Higher Revenue but Posts a Loss
The Wall Street Journal âĸ 2026-05-01T10:37:00Z
Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026
Insider Monkey âĸ 2026-05-01T09:22:19Z
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran
Insider Monkey âĸ 2026-04-23T07:29:55Z
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
Insider Monkey âĸ 2026-04-17T13:58:30Z
Arbutus: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-23T11:39:29Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $14,083,000 | $6,171,000 | $18,141,000 | $39,019,000 |
| Operating Revenue | $14,083,000 | $6,171,000 | $18,141,000 | $39,019,000 |
| Expenses | ||||
| Interest Expense | $97,000 | $137,000 | $459,000 | $1,726,000 |
| Total Expenses | $41,134,000 | $76,145,000 | $96,175,000 | $102,242,000 |
| Other Income Expense | $-10,421,000 | $-6,394,000 | $-44,000 | $-2,255,000 |
| Net Non Operating Interest Income Expense | $3,971,000 | $6,448,000 | $5,229,000 | $466,000 |
| Interest Expense Non Operating | $97,000 | $137,000 | $459,000 | $1,726,000 |
| Operating Expense | $41,134,000 | $76,145,000 | $96,175,000 | $102,242,000 |
| General And Administrative Expense | $15,893,000 | $22,108,000 | $22,475,000 | $17,834,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-33,501,000 | $-69,920,000 | $-72,849,000 | $-69,456,000 |
| Net Interest Income | $3,971,000 | $6,448,000 | $5,229,000 | $466,000 |
| Interest Income | $4,068,000 | $6,585,000 | $5,688,000 | $2,192,000 |
| Normalized Income | $-23,080,000 | $-63,526,000 | $-72,805,000 | $-67,674,550 |
| Net Income From Continuing And Discontinued Operation | $-33,501,000 | $-69,920,000 | $-72,849,000 | $-69,456,000 |
| Total Operating Income As Reported | $-38,160,000 | $-76,319,000 | $-78,103,000 | $-65,456,000 |
| Net Income Common Stockholders | $-33,501,000 | $-69,920,000 | $-72,849,000 | $-69,456,000 |
| Net Income | $-33,501,000 | $-69,920,000 | $-72,849,000 | $-69,456,000 |
| Net Income Including Noncontrolling Interests | $-33,501,000 | $-69,920,000 | $-72,849,000 | $-69,456,000 |
| Net Income Continuous Operations | $-33,501,000 | $-69,920,000 | $-72,849,000 | $-69,456,000 |
| Pretax Income | $-33,501,000 | $-69,920,000 | $-72,849,000 | $-65,012,000 |
| Special Income Charges | $-10,435,000 | $-6,345,000 | $-69,000 | $-2,233,000 |
| Interest Income Non Operating | $4,068,000 | $6,585,000 | $5,688,000 | $2,192,000 |
| Operating Income | $-27,051,000 | $-69,974,000 | $-78,034,000 | $-63,223,000 |
| Earnings From Equity Interest | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.17 | $-0.38 | $-0.44 | $-0.46 |
| Basic EPS | $-0.17 | $-0.38 | $-0.44 | $-0.46 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-473,550 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-22,620,000 | $-62,009,000 | $-70,942,000 | $-59,604,000 |
| Total Unusual Items | $-10,421,000 | $-6,394,000 | $-44,000 | $-2,255,000 |
| Total Unusual Items Excluding Goodwill | $-10,421,000 | $-6,394,000 | $-44,000 | $-2,255,000 |
| Reconciled Depreciation | $363,000 | $1,380,000 | $1,404,000 | $1,427,000 |
| EBITDA (Bullshit earnings) | $-33,041,000 | $-68,403,000 | $-70,986,000 | $-61,859,000 |
| EBIT | $-33,404,000 | $-69,783,000 | $-72,390,000 | $-63,286,000 |
| Diluted Average Shares | $191,599,600 | $185,608,874 | $165,960,379 | $150,939,337 |
| Basic Average Shares | $191,599,600 | $185,608,874 | $165,960,379 | $150,939,337 |
| Diluted NI Availto Com Stockholders | $-33,501,000 | $-69,920,000 | $-72,849,000 | $-69,456,000 |
| Gain On Sale Of Ppe | $674,000 | $0 | - | - |
| Restructuring And Mergern Acquisition | $11,109,000 | $6,345,000 | $69,000 | $2,233,000 |
| Gain On Sale Of Security | $14,000 | $-49,000 | $25,000 | $-22,000 |
| Research And Development | $25,241,000 | $54,037,000 | $73,700,000 | $84,408,000 |
| Selling General And Administration | $15,893,000 | $22,108,000 | $22,475,000 | $17,834,000 |
| Other Gand A | $15,893,000 | $22,108,000 | $22,475,000 | $17,834,000 |
| Tax Provision | - | $0 | $0 | $4,444,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
Fetched: 2026-06-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $76,576,000 | $97,366,000 | $106,018,000 | $136,852,000 |
| Total Assets | $94,618,000 | $131,707,000 | $144,401,000 | $195,419,000 |
| Total Non Current Assets | $162,000 | $4,391,000 | $12,374,000 | $44,280,000 |
| Other Non Current Assets | $130,000 | $34,000 | - | $103,000 |
| Current Assets | $94,456,000 | $127,316,000 | $132,027,000 | $151,139,000 |
| Other Current Assets | $1,538,000 | $2,284,000 | $4,248,000 | $2,874,000 |
| Receivables | $1,447,000 | $2,409,000 | $1,776,000 | $1,352,000 |
| Accounts Receivable | $1,447,000 | $2,409,000 | $1,776,000 | $1,352,000 |
| Cash Cash Equivalents And Short Term Investments | $91,471,000 | $122,623,000 | $126,003,000 | $146,913,000 |
| Cash And Cash Equivalents | $18,008,000 | $36,330,000 | $26,285,000 | $30,776,000 |
| Investmentin Financial Assets | - | $0 | $6,284,000 | $37,363,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $746,000 | $1,289,000 | $1,768,000 | $2,187,000 |
| Long Term Debt And Capital Lease Obligation | $199,000 | $806,000 | $1,343,000 | $1,815,000 |
| Current Debt And Capital Lease Obligation | $547,000 | $483,000 | $425,000 | $372,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $18,042,000 | $34,341,000 | $38,383,000 | $58,567,000 |
| Total Non Current Liabilities Net Minority Interest | $12,036,000 | $18,723,000 | $15,896,000 | $25,710,000 |
| Other Non Current Liabilities | $11,837,000 | $15,054,000 | $14,553,000 | $17,896,000 |
| Non Current Deferred Liabilities | $0 | $2,863,000 | $0 | $5,999,000 |
| Current Liabilities | $6,006,000 | $15,618,000 | $22,487,000 | $32,857,000 |
| Other Current Liabilities | $640,000 | - | - | - |
| Current Deferred Liabilities | $0 | $7,571,000 | $11,791,000 | $16,456,000 |
| Payables And Accrued Expenses | $4,819,000 | $7,564,000 | $10,271,000 | $16,029,000 |
| Payables | $1,173,000 | $2,316,000 | $3,223,000 | $3,520,000 |
| Accounts Payable | $1,173,000 | $2,316,000 | $3,223,000 | $3,520,000 |
| Equity | ||||
| Common Stock Equity | $76,576,000 | $97,366,000 | $106,018,000 | $136,852,000 |
| Total Equity Gross Minority Interest | $76,576,000 | $97,366,000 | $106,018,000 | $136,852,000 |
| Stockholders Equity | $76,576,000 | $97,366,000 | $106,018,000 | $136,852,000 |
| Gains Losses Not Affecting Retained Earnings | $-48,098,000 | $-48,135,000 | $-48,421,000 | $-50,488,000 |
| Other Equity Adjustments | $-48,098,000 | $-48,135,000 | $-48,421,000 | $-50,488,000 |
| Retained Earnings | $-1,380,073,000 | $-1,346,572,000 | $-1,276,652,000 | $-1,203,803,000 |
| Other | ||||
| Ordinary Shares Number | $192,531,225 | $189,963,492 | $169,867,414 | $157,455,363 |
| Share Issued | $192,531,225 | $189,963,492 | $169,867,414 | $157,455,363 |
| Tangible Book Value | $76,576,000 | $97,366,000 | $106,018,000 | $136,852,000 |
| Invested Capital | $76,576,000 | $97,366,000 | $106,018,000 | $136,852,000 |
| Working Capital | $88,450,000 | $111,698,000 | $109,540,000 | $118,282,000 |
| Capital Lease Obligations | $746,000 | $1,289,000 | $1,768,000 | $2,187,000 |
| Total Capitalization | $76,576,000 | $97,366,000 | $106,018,000 | $136,852,000 |
| Additional Paid In Capital | $83,318,000 | $82,048,000 | $81,270,000 | $72,406,000 |
| Capital Stock | $1,421,429,000 | $1,410,025,000 | $1,349,821,000 | $1,318,737,000 |
| Common Stock | $1,421,429,000 | $1,410,025,000 | $1,349,821,000 | $1,318,737,000 |
| Non Current Deferred Revenue | $0 | $2,863,000 | $0 | $5,999,000 |
| Long Term Capital Lease Obligation | $199,000 | $806,000 | $1,343,000 | $1,815,000 |
| Current Deferred Revenue | $0 | $7,571,000 | $11,791,000 | $16,456,000 |
| Current Capital Lease Obligation | $547,000 | $483,000 | $425,000 | $372,000 |
| Current Accrued Expenses | $3,646,000 | $5,248,000 | $7,048,000 | $12,509,000 |
| Net PPE | $32,000 | $4,357,000 | $6,090,000 | $6,814,000 |
| Accumulated Depreciation | $-213,000 | $-12,996,000 | $-11,900,000 | $-10,801,000 |
| Gross PPE | $245,000 | $17,353,000 | $17,990,000 | $17,615,000 |
| Leases | $0 | $8,590,000 | $8,590,000 | $8,590,000 |
| Machinery Furniture Equipment | $245,000 | $477,000 | $391,000 | $391,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $73,463,000 | $86,293,000 | $99,718,000 | $116,137,000 |
| Investments And Advances | - | $0 | $6,284,000 | $37,363,000 |
| Held To Maturity Securities | - | $0 | $6,284,000 | $37,363,000 |
| Other Properties | - | $8,286,000 | $9,009,000 | $8,634,000 |
| Available For Sale Securities | - | - | - | $37,363,000 |
| Preferred Stock | - | - | - | - |
Fetched: 2026-06-02
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-39,637,000 | $-65,032,000 | $-86,944,000 | $-35,868,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-39,637,000 | $-64,850,000 | $-85,936,000 | $-35,356,000 |
| Cash Flow From Continuing Operating Activities | $-39,637,000 | $-64,850,000 | $-85,936,000 | $-35,356,000 |
| Operating Gains Losses | $-674,000 | - | $-20,000 | - |
| Investing Activities | ||||
| Investing Cash Flow | $15,580,000 | $22,948,000 | $50,773,000 | $-74,942,000 |
| Cash Flow From Continuing Investing Activities | $15,580,000 | $22,948,000 | $50,773,000 | $-74,942,000 |
| Capital Expenditure | - | $-182,000 | $-1,008,000 | $-512,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $44,123,000 | $29,852,000 | $20,324,000 |
| Financing Cash Flow | $5,721,000 | $51,996,000 | $30,647,000 | $31,814,000 |
| Cash Flow From Continuing Financing Activities | $5,721,000 | $51,996,000 | $30,647,000 | $31,814,000 |
| Net Common Stock Issuance | $0 | $44,123,000 | $29,852,000 | $20,324,000 |
| Common Stock Issuance | $0 | $44,123,000 | $29,852,000 | $20,324,000 |
| Other | ||||
| End Cash Position | $18,008,000 | $36,330,000 | $26,285,000 | $30,776,000 |
| Beginning Cash Position | $36,330,000 | $26,285,000 | $30,776,000 | $109,282,000 |
| Effect Of Exchange Rate Changes | $14,000 | $-49,000 | $25,000 | $-22,000 |
| Changes In Cash | $-18,336,000 | $10,094,000 | $-4,516,000 | $-78,484,000 |
| Proceeds From Stock Option Exercised | $5,721,000 | $7,873,000 | $795,000 | $11,490,000 |
| Net Investment Purchase And Sale | $15,216,000 | $23,130,000 | $51,761,000 | $-74,430,000 |
| Sale Of Investment | $155,277,000 | $164,639,000 | $132,270,000 | $56,000,000 |
| Purchase Of Investment | $-140,061,000 | $-141,509,000 | $-80,509,000 | $-130,430,000 |
| Net PPE Purchase And Sale | $364,000 | $-182,000 | $-988,000 | $-512,000 |
| Sale Of PPE | $364,000 | $0 | $20,000 | $0 |
| Purchase Of PPE | $0 | $-182,000 | $-1,008,000 | $-512,000 |
| Change In Working Capital | $-10,023,000 | $-2,829,000 | $-18,233,000 | $29,243,000 |
| Change In Other Working Capital | $-10,434,000 | $-1,357,000 | $-10,664,000 | $22,455,000 |
| Change In Other Current Liabilities | $-557,000 | $-430,000 | $-444,000 | $-405,000 |
| Change In Payables And Accrued Expense | $-2,105,000 | $-2,707,000 | $-5,758,000 | $5,216,000 |
| Change In Prepaid Assets | $1,698,000 | $2,298,000 | $-943,000 | $2,430,000 |
| Change In Receivables | $1,375,000 | $-633,000 | $-424,000 | $-453,000 |
| Changes In Account Receivables | $1,375,000 | $-633,000 | $-424,000 | $-453,000 |
| Other Non Cash Items | $-3,217,000 | $501,000 | $-3,343,000 | $-3,698,000 |
| Stock Based Compensation | $6,953,000 | $8,986,000 | $9,301,000 | $7,182,000 |
| Asset Impairment Charge | $2,811,000 | $167,000 | $0 | - |
| Amortization Of Securities | $-2,349,000 | $-3,135,000 | $-2,196,000 | $-54,000 |
| Depreciation Amortization Depletion | $363,000 | $1,380,000 | $1,404,000 | $1,427,000 |
| Depreciation And Amortization | $363,000 | $1,380,000 | $1,404,000 | $1,427,000 |
| Depreciation | $363,000 | $1,380,000 | $1,404,000 | $1,427,000 |
| Gain Loss On Sale Of PPE | $-674,000 | $0 | $-20,000 | $0 |
| Net Income From Continuing Operations | $-33,501,000 | $-69,920,000 | $-72,849,000 | $-69,456,000 |
| Change In Payable | - | - | - | $5,216,000 |
| Change In Account Payable | - | - | - | $5,216,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | - |
Fetched: 2026-06-02